Novel co-operation between eotaxin and substance-P in inducing eosinophil-derived neurotoxin release. by El-Shazly, A & Ishikawa, T
Novel  co-operation  between
eotaxin  and  substance-P  in  inducing
eosinophil-derived  neurotoxin
release
Amr  El-ShazlyCA and  Takeru  Ishikawa
Kumamoto  University,  School  of  Medicine,
Department  of  Otolaryngology, Honjo  1± 1-1,
Kumamoto  860,  Japan
CACorresponding Author
Present Address: Dr Amr El-Shazly, Department of
Otolaryngology and Head and Neck Surgery, St George’s
Hospital – London University, Blackshaw Road, London
SW17 OQT , UK
Tel/Fax: +44 121 4720478
Email: amr@el-shazly.u-net.com
EOSINOPHILS,  chemokines,  and  neuropeptides  are
thought to play effector roles in the pathogenesis of
allergic diseases such as rhinitis. Eotaxin is a novel
C–C chemokine with a potent and relatively specific
eosinophil chemoattractant activity that binds selec-
tively  to  CCR3  receptor,  however,  its  activity  in
inducing  eosinophil  granules  proteins  release  is
poorly  characterized.  This  study  was  performed  to
determine whether eotaxin primes eosinophil exocy-
tosis and whether this co-operates with the sensory
neuroimmune-axis.  In  the  present  communication,
we  show  that  10  ng/ml  eotaxin  primed  normal
human  eosinophil  for  exaggerated  eosonophil-
derived neurotoxin (EDN) release stimulated by 10–8
M Substance-P (SP). This novel priming was blocked
by; 7B11 and Herbimycin A (HA), the CCR3 antagonist
and the tyrosine kinase inhibitor, respectively. SDS-
Page studies showed significant  tyrosine phosphor-
ylation of several protein residues induced by 10–8 M
SP only after priming with 10 ng/ml eotaxin. These
results  demonstrate  a  novel  co-operation  between
eotaxin and SP in inducing eosinophil cytotoxicity,
which  at  least  in  part  involves  tyrosine  kinases
pathway(s).
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Introduction
Allergic  rhinitis  is  a  chronic  inflammatory  disease
which  is  characterized  by  tissue  eosinophilia.  A
number of allergic mediators act as chemoattractant
for eosinophil, however, eotaxin the C–C chemokine
which selectively binds to CCR3 receptor is a potent
and relatively specific eosinophil chemoattractant and
its role in rhinitis is well reported.1
After  tissue  infiltration  with  eosinophils,  their
cytotoxic function is activated by the proper stimuli
to secrete a number of cationic proteins including the
major basic protein,  the eosinophil  peroxidase, the
eosinophil  cationic  protein  and  the  eosinophil-
derived  neurotoxin.  The  release  of  these  proteins
contribute  to  the  hypersensitivity  reaction  and  to
tissue damage of the airway.2
Among  the  proper  stimuli  of  EDN  release  is  the
neuropeptide  SP,  which  is  released  from  the  nasal
sensory neurones.3
The  current  study  was  designed  to  investigate
whether  eotaxin  possesses  a  priming  activity  for
eosinophil  exocytosis  and  whether  this  works  in
synergy with SP.
Materials  and  methods
Eosinophil  purification
Eosinophils  from  healthy  volunteers  were  purified
from  venous  blood  anticoagulated  with  heparin  by
Percoll  discontinuous  density  gradients  centrifuga-
tion.  In  short,  heparanised  blood  was  sedimented
with 6% dextran for 30 min at room temperature. The
leukocyte-rich  plasma  was  collected  and  washed
twice  with  Hank’s  balanced  salt  solution  (HBSS)
containing 2% fetal bovine serum (FBS). Eosinophils
were  then  separated  by  Percoll  discontinuous  gra-
dients centrifugation.  Gradients consisted  of  a  mix-
ture of Percoll and HBSS adjusted to 2.5ml of 78%,
71% and 56% Percoll, respectively in 15 ml polystrene
tubes, and recovered  cells  suspended in  HBSS  con-
taining 2% FBS  were overlaid. The tubes were then
centrifuged at 4003 g for 30 min. The pellet and the
lowest band granulocytes were collected, and sede-
minted red blood cells were removed by hypodense
lysis. These lymphocyte- and monocyte-free granulo-
cytes  were  incubated  with  CD16  immunomagnetic
beads for 30 min to eliminate unwanted neutrophils.
High  purity  >98%  eosinophilic  granulocytes  were
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sorting. Cell viabilities were >95% as judged by trypan
blue exclusion.
Eosinophil  degranulation  and  assay  of  EDN
concentration
Freshly purified eosinophils were suspended in Ros-
well  Park  Memorial  Institute  (RPMI)  1640  medium
containing 10% FBS and adjusted to 13 106 cells/ml.
Eosinophil degranulation was induced by dilutions of
either  10  ng/ml  eotaxin  (Funakoshi  Co.,  Tokyo,
Japan), or 10–8 M SP (Sigma, St Lous, MO) using 96 flat
bottom  plates  (Nunc,  Denmark).  Briefly,  100  m l  of
each stimulus suspended in the same culture medium
as eosinophils (RPMI) were added to 100  m l of the
purified eosinophil, after 1 h incubation, supernatants
were carefully collected. EDN concentrations in the
supernatants  were  analysed  by  radioimmunoassay
(RIA)  using  EDN  RIA  kits  (Pharmacia,  Uppsala,
Sweden). The total content of EDN was measured by
lysing eosinophils with 1% Nonidet P-40 (NP-40). As
for the priming experiments, cells were incubated for
15 min with 10 ng/ml eotaxin, washed twice, resus-
pended in the culture medium and their EDN release
induced by 10–8 M SP was tested in the same way as
described above.
Western  blotting
Cells  were  washed  with Hepes-buffered  saline  con-
taining 1 mM Na3VO4 (pH 7.4) at 4°C, and then lysed
in triton X-100 lysis buffer (50 mM Hepes, pH 7.4, 1%
triton  X-100,  4  mM  EDTA,  100  mM  NaF,  1  mM
Na3VO4, 50 m g/ml aprotinin,  200  m M leupeptin, 50
m M  pepstatin  A,  and  1  mM  phenylmethylsulfonyl
fluoride) at 4°C for 30 min. Lysates were subjected to
SDS-PAGE and electrotransferred onto polyvinylidene
difluoride membranes for western blotting.
Statistical  analysis
Results  are  expressed  as  mean  ±SEM  and  were
analysed by paired t-test using statview software on an
apple  Macintosh  computer. A  value  of  p<0.05  was
considered significant.
Results  and  Discussion
A primer is an agent at non functionally stimulatory
dose(s), prepare the cell, making it ready to function
to suboptimal dose from the proper stimuli. Accord-
ingly, 10 ng/ml eotaxin was chosen for the following
experiments  since  it  is  the  dose  which  does  not
directly induce functional response i.e. EDN release4
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FIG. 1. Relationship between the priming activity of eotaxin in EDN release and tyrosine phosphorylation. (A) EDN
secretagouge  activity  of  10  ng/ml  eotaxin  and  10
± 8 M  SP.  Results  are  of  a  1h  degranulation  assay  and  represent  ±   SEM  of  6
independent  experiments  performed  in  duplicate.  (B)  Priming  activity  of  10  ng/ml  eotaxin  in  EDN  release  stimulated  by  10
± 8 M
SP.  Asterisk  indicates p =0.0001.  Results  are  of  8  independent  experiments  performed  in  duplicate,  ±   SEM.  (C)  Modulation  of
eotaxin  priming  activity  in  EDN  release  by  7B11  and  herbimycin  A.  Asterisk  indicates p =0.0001.  Results  are  of  6± 8  independent
experiments performed in duplicate, ±  SEM. (D) Association of tyrosine phosphorylation with CCR3 stimulation. Normal
human  eosinophils  were  pre-incubated  for  15min  at  37¡C  with  10  ng/ml  eotaxin  (lanes  5  and  6)  or  for  15min  with  buffer  only
(lanes  3  and  4),  cells  were  washed  three  times  followed  by  10
± 8 M  SP  stimulation  for  a  further  30min  at  37¡C.  Lanes  1  and  2
represent control cells stimulated  with buffer only. Equal amounts of Triton X-100 cell lysates were analysed  by western
blotting  with  4G10  mAb  for  phosphorylation.  Molecular  size  markers  are  indicated  on  the  right  (kDa).  Experiment  shown  is  one
representative  of  three  independent  experiments  performed  in  duplicate.(Fig. 1A) and thus was ideal for the priming experi-
ments,  similarly  10–8 M  SP  which  is  suboptimal
stimulatory dose3 (Fig. 1A) was tested in the following
experiments to demonstrate whether synergy exists
between eotaxin and SP. As can be seen in Fig. 1B,
10–8 M SP caused a significant EDN release only after
the  cells  were  first  primed  with  10  ng/ml  eotaxin
(compare bar 5 with bar 6).
Recently there is increasing evidence that tyrosine
kinases  are  involved  in  EDN  release  pathway(s).5
Therefore  we  next  blocked  CCR3  with  7B11  and
tyrosine kinases with herbimycin A, before priming
eosinophil with eotaxin. It was shown that both agents
significantly blocked the priming activity of eotaxin
(Fig. 1C, compare bars 9 and 10 with bar 8). To further
gain insight into the role of tyrosine phosphorylation
in eotaxin priming activity, we studied the phosphor-
ylation pattern in normal eosinophils by SP in the same
dynamics  as  the  pharmacological  assay  i.e.  in  the
presence and absence of 10 ng/ml eotaxin. As can be
seen in Fig. 1D, 10–8 M SP did not induce any tyrosine
phosphorylation (Compare lanes 3 and 4 with lanes 1
and 2), however, the same dose caused a significant
phosphorylation of several protein residues, only after
priming  the  cells  with  10  ng/ml eotaxin  (compare
lanes 5 and 6 with lanes 3 and 4). It is of note that 10
ng/ml eotaxin stimulation did not cause any tyrosine
phosphorylation (data not shown).
These  findings  suggest  that  low  dose  eotaxin
stimulation  of  CCR3  may  prime  human  eosinophil
cytotoxic  functional  response  against  SP  through  a
change  in  the  signal  transduction  which at  least  in
part involves tyrosine kinases.
We  propose  that  eotaxin  at  low  non  functional
stimulatory  dose  primes  eosinophil  for  exaggerated
inflammatory response by SP. If so, our data demon-
strate a new indirect property of eotaxin in activating
eosinophil exocytosis and provide a novel model of
synergism  at  the  cellular  and  molecular  levels  in
hypersensitivity disease, which could be a potential
target for therapy.
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